Bio Light Headed for Biggest Gain in Month on Glaucoma Permit
Bio Light Israeli Life Sciences Investments Ltd. (BOLT) headed for its biggest gain in more than a month after the developer of drugs and medical technology said a unit got approval to market a glaucoma surgery device.
The shares advanced 2.1 percent, headed for the biggest gain since Feb. 21, to 0.197 shekel at 11 a.m. in Tel Aviv, giving the Ramat Gan, Israel-based company a market value of 35 million shekels ($9.3 million).
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.